Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 8/20 | 0.51 |
| ▸ | BRAF | P15056 | 8/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442865 | 0.92 | MCHR1 (0.54) | EPHX2MCHR1PIK3CAMTORPIK3CG | |
| SCHEMBL15689339 | 0.90 | RAF1 (0.52) | IDH2RAF1BRAFAKT1EPHX2 | |
| SCHEMBL15141198 | 0.89 | CDK8 (0.54) | IDH2RAF1BRAFEPHX2MCHR1 | |
| SCHEMBL12812449 | 0.89 | BRAF (0.61) | RAF1BRAF | |
| SCHEMBL1444063 | 0.87 | BRAF (0.55) | BRAFEPHX2MCHR1TEKKDR | |
| SCHEMBL14783150 | 0.87 | RAF1 (0.53) | IDH2RAF1BRAFAKT1EPHX2 | |
| SCHEMBL29590867 | 0.87 | RAF1 (0.53) | IDH2RAF1BRAFAKT1EPHX2 | |
| SCHEMBL1442857 | 0.86 | AKT1 (0.51) | RAF1BRAFAKT1MCHR1 | |
| SCHEMBL15141095 | 0.86 | EPHX2 (0.56) | IDH2RAF1BRAFAKT1EPHX2 | |
| SCHEMBL12812455 | 0.86 | MTOR (0.56) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | claimed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | claimed |
| CN-102596932-A | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | claimed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | claimed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | claimed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | IDH2 897/4885RAF1 29/4885BRAF 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.